Gilead to face HIV antitrust claims

05-03-2020

Rory O'Neill

Gilead to face HIV antitrust claims

chrisdorney / Shutterstock.com

Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.


Gilead Sciences, Bristol-Myers Squibb, Japan Tobacco, Johnson & Johnson, HIV, cART, antitrust, competition

More on this story

Gilead hit with antitrust suit over HIV drugs
16-01-2020

LSIPR